Ophthotech is changing its name to Iveric Bio and will focus on developing novel gene therapy solutions for orphan inherited retinal diseases, according to a press release.
“We are excited about our rebranding and corporate name change reflecting our transition to a gene therapy-focused company developing treatments for patients with orphan inherited retinal diseases,” Glenn P. Sblendorio, CEO and president of Iveric bio, said in the release. “We are executing a strategy that leverages our retinal expertise and provides a clear path forward with multiple orphan IRD gene
Uncategorized